A Cochrane systematic review has challenged the standard sequencing of neo-adjuvant treatment for early breast cancer with anthracycline-based chemotherapy first followed by a taxane. The review, conducted by medical oncologists at Concord Hospital, Sydney, found equivalent outcomes for both sequences in which either taxane or anthracycline chemotherapy were delivered first in a neo-adjuvant setting. However, ...
More data needed for taxane-first sequence in breast cancer: Cochrane
By Michael Woodhead
20 Feb 2019